Arlon Advisor

Arlon Advisor

Pablo Legorreta established Arlon Advisor in 2011 after two decades building Royalty Pharma into the largest life-sciences royalty aggregator, applying that cash-flow compounding lens to the fragmented mid-market food sector. The firm operates as the dedicated investment platform for Legorreta family capital, structured with a permanent-hold mandate that avoids the exit clock carried by traditional private equity funds. Its focus falls on established businesses in dairy, meat, seafood, specialty ingredients and food-safety technology, primarily across North and Latin America. Arlon takes majority-control positions ranging from $50 million to $300 million per deal, using no outside limited partners and no fund lifecycle — each investment competes for capital alongside the next, directly reflecting Legorreta's conviction. Historically the firm has held concentrated stakes in companies such as Grupo Farcomer, a Panamanian dairy and juice processor, and Stavis Seafoods, a Boston-based import-export distributor serving the US foodservice channel. The portfolio spans primary meat and dairy processing in Mexico and Brazil, traceable aquaculture sourcing in Chile, and specialty ingredient manufacturing for branded CPG companies, with occasional bolt-on acquisitions in adjacent categories like food-grade logistics and agricultural inputs. Recent activity is difficult to surface from public records — the firm maintains no press strategy and discloses no aggregate AUM — but consistent hiring across its New York office in late 2023 and early 2024 for mid-level food-industry deal professionals and operational improvement roles signals steady portfolio activity and possible bolt-on execution. Arlon has not established adjacent family-office vehicles such as a private foundation or consumer venture arm under the Legorreta name, preferring co-investment directly through the parent platform. What structurally distinguishes Arlon is its single-balance-sheet, permanent-capital architecture: no fundraising cycle, no limited-partner advisory committee, and no predetermined divestiture windows. This allows it to hold food assets for twelve or fifteen years — or indefinitely — matching the biological crop and herd cycles that fund-life private equity cannot accommodate. Where conventional agri investors manage commodity risk through seasonal exits, Arlon absorbs volatility, deploys patient operating capital into plant-level safety upgrades and cold-chain integration, and compounds profitability without reselling to the next sponsor.